Revance Therapeutics, Inc. (RVNC)
USD 3.07
(0.0%)
USD 3.07
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -216.57 Million | -193.54 Million | -221.53 Million | -178.5 Million | -106.16 Million | -104.24 Million |
| Net Income | -323.98 Million | -356.42 Million | -281.31 Million | -282.08 Million | -159.42 Million | -142.56 Million |
| Depreciation & Amortization | 13.69 Million | 39.14 Million | 19.85 Million | 10.25 Million | 2.9 Million | 1.72 Million |
| Deferred income taxes | -99.54 Million | - | 89 Thousand | -2.72 Million | -2.64 Million | -2.56 Million |
| Stock-based compensation | 49.18 Million | 52.34 Million | 43.43 Million | 36.45 Million | 17.92 Million | 16.27 Million |
| Change in working capital | -43.88 Million | 665 Thousand | -4.77 Million | 39.97 Million | 34.27 Million | 22.71 Million |
| Other non-cash items | 189.33 Million | 70.72 Million | 1.17 Million | 19.63 Million | 810 Thousand | 175 Thousand |
| Investing Cash Flow | 109.74 Million | -138.79 Million | -29.66 Million | 12.13 Million | -17.59 Million | -107.02 Million |
| Investments in PPE | -6.88 Million | -23.01 Million | -18.07 Million | -4.21 Million | -3.23 Million | -7.09 Million |
| Acquisitions | - | 19.8 Million | 7.7 Million | -818 Thousand | 8000.00 | 100 Thousand |
| Investment purchases | -263.92 Million | -347.96 Million | -183.59 Million | -259.3 Million | -331.36 Million | -314.91 Million |
| Sales/Maturities of investments | 385.43 Million | 232.17 Million | 172 Million | 276.46 Million | 317 Million | 213.43 Million |
| Other Investing Activities | -4.88 Million | -19.8 Million | -7.7 Million | 17.04 Million | -14.36 Million | 1.44 Million |
| Financing Cash Flow | 136.56 Million | 331.69 Million | 29.86 Million | 331.48 Million | 221.65 Million | 1.78 Million |
| Debt repayment | -30.16 Million | -11.09 Million | - | -278.31 Million | - | -932 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -8.21 Million | -6.49 Million | -8.18 Million | -8.44 Million | -1.37 Million | -2.21 Million |
| Common Stock Issuance | 114.62 Million | 248.01 Million | 38.05 Million | 83.94 Million | 222.84 Million | 4.92 Million |
| Other Financing Activities | 52.1 Million | 107.76 Million | 38.05 Million | 804.15 Million | 195 Thousand | 2.71 Million |
| Accounts receivables | -16.33 Million | -7.99 Million | -1.51 Million | 12.13 Million | 27 Million | -26.95 Million |
| Accounts payables | 6.9 Million | -5.44 Million | -1.82 Million | 4.42 Million | -360 Thousand | 1.69 Million |
| Inventory | -14.91 Million | -6 Million | -4.27 Million | -5.87 Million | -27 Million | -3.17 Million |
| Other working capital | -19.53 Million | 20.11 Million | 2.84 Million | 29.28 Million | 34.63 Million | 51.15 Million |
| Cash at beginning of period | 108.96 Million | 115.66 Million | 337 Million | 171.89 Million | 73.98 Million | 283.47 Million |
| Cash at end of period | 137.87 Million | 115.01 Million | 115.66 Million | 337 Million | 171.89 Million | 73.98 Million |
| Capital Expenditure | -6.88 Million | -23.01 Million | -18.07 Million | -4.21 Million | -3.23 Million | -7.09 Million |
| Effect of forex changes on cash | -818 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | 28.91 Million | -652 Thousand | -221.33 Million | 165.11 Million | 97.9 Million | -209.49 Million |
| Free Cash Flow | -223.46 Million | -216.55 Million | -239.61 Million | -182.71 Million | -109.39 Million | -111.33 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -37.46 Million | -49.52 Million | -55.69 Million | -323.98 Million | -141.17 Million | -67.31 Million |
| Depreciation & Amortization | 1.42 Million | 1.98 Million | 1.41 Million | 13.69 Million | 2.12 Million | 3.53 Million |
| Deferred income taxes | - | - | - | -99.54 Million | 91.24 Million | -1.44 Million |
| Stock-based compensation | 5.79 Million | 8.99 Million | 8.84 Million | 47.81 Million | 10.28 Million | 15.59 Million |
| Change in working capital | -10.85 Million | -23.13 Million | 3.17 Million | -43.88 Million | -14.12 Million | -4.44 Million |
| Other non-cash items | 19.9 Million | 19.86 Million | 3.28 Million | 189.33 Million | 678 Thousand | 701 Thousand |
| Investing Cash Flow | -6.88 Million | -31.7 Million | 2.37 Million | 109.74 Million | 51.58 Million | -39.53 Million |
| Investments in PPE | -470 Thousand | -1.71 Million | -1.77 Million | -6.88 Million | -4.5 Million | 266 Thousand |
| Acquisitions | - | - | - | - | - | 39.79 Million |
| Investment purchases | -91.77 Million | -73.03 Million | -84 Million | -263.92 Million | -51.06 Million | -99.56 Million |
| Sales/Maturities of investments | 87.15 Million | 46.5 Million | 89.65 Million | 385.43 Million | 110.53 Million | 59.76 Million |
| Other Investing Activities | -1.8 Million | -3.46 Million | -1.5 Million | -4.88 Million | -3.38 Million | -39.79 Million |
| Financing Cash Flow | -3.41 Million | 92.82 Million | -1.62 Million | 136.56 Million | 37.46 Million | 97.47 Million |
| Debt repayment | -3.89 Million | -4.22 Million | -2.74 Million | -30.16 Million | -6.61 Million | -6.41 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -40 Thousand | -402 Thousand | -148 Thousand | -8.21 Million | -3.77 Million | -564 Thousand |
| Common Stock Issuance | 522 Thousand | 97.45 Million | 1.26 Million | 114.62 Million | -567 Thousand | 100.18 Million |
| Other Financing Activities | -40 Thousand | -402 Thousand | -148 Thousand | 52.1 Million | 52.75 Million | 4.82 Million |
| Accounts receivables | -6.2 Million | -2.21 Million | -2.26 Million | -16.33 Million | -8.37 Million | -1.67 Million |
| Accounts payables | -371 Thousand | -6.83 Million | 7.02 Million | 6.9 Million | -3.83 Million | -1.39 Million |
| Inventory | -4.71 Million | -2.11 Million | 3.15 Million | -14.91 Million | -6.41 Million | -4.01 Million |
| Other working capital | 432 Thousand | -11.97 Million | -4.74 Million | -19.53 Million | 4.49 Million | 2.62 Million |
| Cash at beginning of period | 133.15 Million | 137.87 Million | 179.59 Million | 108.96 Million | 148.65 Million | 144.09 Million |
| Cash at end of period | 81.72 Million | 133.15 Million | 137.87 Million | 137.87 Million | 186.73 Million | 148.65 Million |
| Capital Expenditure | -470 Thousand | -1.71 Million | -1.77 Million | -6.88 Million | -4.5 Million | 266 Thousand |
| Effect of forex changes on cash | - | - | - | -818 Thousand | - | 8.66 Million |
| Net cash flow / Change in cash | -51.43 Million | -4.72 Million | -41.71 Million | 28.91 Million | 38.08 Million | 4.55 Million |
| Free Cash Flow | -41.59 Million | -67.65 Million | -44.51 Million | -223.46 Million | -55.46 Million | -53.11 Million |
002015
LOV
CVS
RMC
HNR1
300833